The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter phase II study of modified FOLFIRINOX for first-line treatment for advanced urachal cancer (ULTMA; KCSG GU20-03).
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Amgen; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); GI Innovation (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Inkeun Park
No Relationships to Disclose
 
Shinkyo Yoon
Honoraria - MSD Oncology
Consulting or Advisory Role - Boryung Pharmaceuticals; Daiichi Sankyo
 
Sang Joon Shin
No Relationships to Disclose
 
Seong-Hoon Shin
No Relationships to Disclose
 
Kwonoh Park
No Relationships to Disclose
 
Jung Hoon Kim
No Relationships to Disclose
 
Hyo Jin Lee
No Relationships to Disclose